gMed, a Modernizing Medicine Co., completed its rebrand to become Modernizing Medicine Gastroenterology.
A series of studies confirmed Synergy Pharmaceuticals’ Trulance was effective in older patients with chronic idiopathic constipation or irritable bowel syndrome with constipation.
Allergan launched two global clinical research programs for its inflammatory bowel disease drug, brazikumab.
CSA Medical received $23 million in venture debt and equity financing to advance its pair of cryospray therapies.
A single dose of Janssen Pharmaceuticals’ Stelara induced clinical remission in patients with moderate to severe ulcerative colitis,
Takeda is presenting long-term efficacy and real-world data for Entyvio at ACG 2018 in Philadelphia Oct. 5-10.
CDx Diagnostics presented Wide Area Transepithelial Sampling with 3D Tissue Analysis data showing crypt dysplasia played a role in high-grade esophageal dysplasia and esophageal cancer at ACG 18, Oct. 5-10 in Philadelphia.
More articles on gastroenterology:
Takeda presents 3 studies examining Entyvio’s long-term efficacy
Janssen Pharmaceuticals’ ulcerative colitis drug induces clinical remission — 5 insights
WATS3D confirms crypt dysplasia as a cancer risk factor in Barrett’s esophagus patients — 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
